Table 2.
Clinical and immunological results of phase I and II studies (DC-based vaccines)
| Vaccine | No. of patients treated | Clinical responses | Duration (months) | Immune responses | References |
|---|---|---|---|---|---|
| Dendritic cells with | |||||
| PSMA peptides | 51 | 7 PR (14%) | 6 | Not determined | [67] |
| PSMA peptides | 62 | 11 PR (18%) 8 SD (13%) | 9–18 | Not determined | [68] |
| PAP/GM-CSF (Provenge) | 31 | 3 PR (10%) | 12 | 100% | [74] |
| PAP/GM-CSF (Provenge) | 19 | 3 PR (16%) 1 SD (5%) | 4–48 | Not determined | [75] |
| PSA mRNA (viral vector) | 13 | 6 PR (46%) | 6 | 100% | [78] |
| Telomerase mRNA (viral vector) | 20 | 6 PR (30%) | 4 | 25% | [79] |
| PSA mRNA (viral vectors) only (no DCs) | 64 | 37 SD (58%) | 10 | 32% | [82] |